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Abstract
Background
As plans to expand mass drug treatment campaigns to fight schistosomiasis form, worries
about reliance on praziquantel as the sole available treatment motivate the investigation for
novel antischistosomal compounds. Drug repurposing might be an inexpensive and effec-
tive source of novel antischistosomal leads.
Methodology
1600 FDA approved compounds were first assayed against Schistosoma mansoni schisto-
somula at a concentration of 10 µM. Active compounds identified from this screen were
advanced to the adult worm screen at 33.33 µM, followed by hit characterization. Leads
with complementary pharmacokinetic and toxicity profiles were then selected for in vivo
studies.
Principal Findings
The in vitro screen identified 121 and 36 compounds active against the schistosomula and
adult stage, respectively. Further, in vitro characterization and comparison with already
available pharmacokinetic and toxicity data identified 11 in vivo candidates. Doramectin
(10 mg/kg) and clofazimine (400 mg/kg) were found to be active in vivo with worm burden
reductions of 60.1% and 82.7%, respectively.
Conclusions/Significance
The work presented here expands the knowledge of antischistosomal properties of already
approved compounds and underscores variations observed between target-based and
phenotypic approaches and among laboratories. The two in vivo-active drugs identified in
this study, doramectin and clofazimine are widely available and present as novel drug clas-
ses as starting points for further investigation.
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Author Summary
For a disease of large global health importance, schistosomiasis has a disproportionally
small treatment tool box- only praziquantel is used to treat all 3 major forms of the disease.
While drug discovery can be a long, laborious and expensive process, especially for an
under-funded neglected disease such as schistosomiasis, drug recycling (also termed repo-
sitioning or repurposing) can bypass some of the development processes and offset the
costs. We conducted a drug screening project of 1600 FDA-approved compounds from a
very diverse set of indications against Schistosoma mansoni. The full 1600 compounds
were first screened in vitro against the larval stage of the worm, of which 121 drugs were
identified as active. These hits were then screened on the adult stages of the worm in vitro
where 36 of these hits were also found to be active on the adult stage. The safety and phar-
macokinetic profiles of hit compounds were then compared to their in vitro activity and
11 compounds were chosen for studies in mice. Of these, clofazimine and doramectin
were found to be moderately active, and present new antischistosomal scaffolds with
which further investigations can be pursued. Our findings are placed in context with
results obtained from previous in vitro and in silico chemogenomics work and agreements
and disagreements discussed.
Introduction
Worldwide, schistosomiasis continues to affect the health and quality of life of millions, caus-
ing 3.3 million Disability-Adjusted Life-Years lost [1]. Most of the burden is contained in the
tropics, mostly in Sub-Saharan Africa, where it disproportionally affects children in poor
rural areas [2]. The three principal causative agents are Schistosoma mansoni, Schistosoma
haematobium and Schistosoma japonicum. Infection with any of these three species, when left
untreated, results in chronic inflammation which slowly develops into swelling, fibrosis and
necrosis of the tissues of intestinal organs, the liver or the bladder, as well as a range of other
symptoms which gradually impair the host physiologically and even cognitively [3,4].
The World Health Organisation (WHO) places morbidity control as a priority for treating
schistosomiasis via preventative chemotherapy in the form of mass drug administration cam-
paigns. Treatment targeted at high risk groups, mainly school-aged children, interrupts
advancement to the cumulative damage of chronic stages, which causes most of the disease
burden [5]. To date, this is seen as the most cost-effective strategy, as interruption of transmis-
sion is very difficult, costly and subject to many factors, and vaccine development is still far out
of reach [6,7]. Yet of the 207 million people infected annually, in 2012 only 35 million received
treatment at a given time [4]. Therefore, it has become essential to expand mass treatment
campaigns. Indeed, as many as 235 million children are targeted to receive treatment by 2018
[8].
Nonetheless, we still rely on praziquantel as the sole treatment and the expanded use of this
drug, while positively reducing morbidity, would also increase the potential for praziquantel
resistance [9,10]. Regardless of expansion plans, reliance on one single drug for mass treating a
population is dangerous. The international community has repeatedly stated the need for new
medication, since the drug discovery and development pipeline is dry [11]. Earlier, we reviewed
the ways in which drug repurposing is aiding helminth drug discovery [12] and highlighted
several clinical success stories such as antimalarials for the treatment of schistosomiasis. Drug
repurposing (or repositioning) is the development of new indications from existing, failed or
abandoned drugs and offers some obvious benefits: researchers can piggy-back off the
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availability of pre-clinical data, saving time and costs, making more informed decisions on hit-
to-lead identification and ultimately decreasing the time it takes to bring a drug to market
[13,14].
In the framework of a Gates-funded drug discovery project, overseen by the Drugs for
Neglected Diseases initiative (DNDi), different libraries, including a library of 1600 FDA
approved compounds with diverse classes and initial applications, were screened on Schisto-
soma mansoni. Abdulla and colleagues had previously evaluated a similar library of 2160 com-
pounds on a Puerto Rican strain of S.mansoni, finding many in vitro-active compounds but
no strong in vivo-active candidates [15]. Considering our past experience with strain and hit
cut-off differences [16], we were encouraged to screen the above-mentioned 1600 compound
FDA library in the hopes of identifying strong candidates to test in vivo and to compare our
findings.
In more detail, the full 1600 compound library was initially assayed on newly transformed
schistosomula (NTS- the larval stage). Compounds that reduced NTS viability by 75% were
further tested on adult worms and their activity was compared to their existing pharmacoki-
netic and toxicity profiles before initiating studies in a mouse-S.mansoni infection model.
Finally, we compare our results with findings reported from the above-mentioned screen by
Abdulla et al. and a recent target-based chemogenomics screen of a dataset of 2,114 proteins by
Neves et al. [17], and discuss overlaps and contradictions.
Materials and Methods
Compounds and Media
The FDA Pharmakon compound library was purchased fromMicroSource Discovery Systems,
Inc. (USA). Compounds were delivered in microplates (10 mM, dissolved in DMSO) and kept
at -80°C until use. For in vivo studies, flunarizine hydrochloride, pimozide, nicardipine hydro-
chloride, oxethazaine, menadione, clofazimine, doramectin and metitepine mesylate were pur-
chased from Sigma-Aldrich (Buchs, Switzerland) and fendiline hydrochloride, manidipine
hydrochloride and lomerizine hydrochloride were purchased from Santa-Cruz Biotechnology
(California, USA). Hanks Balanced Salt Solution (HBSS) was obtained from Gibco (Lucerne,
Switzerland). Culture medium components for NTS and adult worms were obtained as follows:
Medium 199 RPMI 1640 and penicillin (100 U/ml) and streptomycin (100 μg/ml) were pur-
chased from Lubioscience (Lucerne, Switzerland) whereas inactivated fetal calf serum (iFCS)
was purchased from Connectorate AG (Dietikon, Switzerland).
Schistosoma mansoni Larval In Vitro Assay
NTS were obtained using a transformation method described previously [18]. Briefly, cercariae
(Liberian strain) were harvested from infected intermediate host snails (Biomphalaria glabrata)
after several hours’ exposure to light. The collected cercarial suspension was cooled, centrifuged
and pipetted, and vortexed vigorously in HBSS to remove the tails. The suspension was rinsed
in cool HBSS to remove the tails and the resulting NTS suspension was adjusted to a concentra-
tion of 100 NTS per 50 μl in NTS culture medium (Medium 199 supplemented with 5% iFCS
and 1% penicillin/streptomycin). The NTS suspension was then incubated at 37°C, 5% CO2
in ambient air for 24 hours. Drugs were first tested at a concentration of 10 μM on NTS. The
worms were incubated in culture medium and the test compounds in a 96-well plate in tripli-
cate for 72 hours. Thereafter, they were assessed microscopically using a viability scale previ-
ously described [16], which scores the morphology and motility of the NTS (3 = motile, no
changes to morphology; 2 = reduced motility and/or some damage to tegument noted;
1 = severe reduction to motility and/or damage to tegument observed; 0 = dead). Hits were
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characterized as compounds that achieved an average viability score of 0.5 or less (corresponds
to NTS viability of 25%).
In Vitro Drug Sensitivity Assay on Schistosoma mansoni Adult Worms
Compounds identified as hits in the NTS drug assay were further tested on adult worms. Mice
were infected as detailed in the in vivo studies section below and the infection was allowed to
mature for 7 weeks. Mice were then euthanized with CO2 and their intestinal apparatus was
dissected. Worms were collected from the hepatic portal and mesenteric veins and subse-
quently rinsed and stored in culture medium (RPMI supplemented with 5% iFCS and 1% peni-
cillin/streptomycin) at 37°C, 5% CO2 until use. In a 24-well plate, 2–4 worm pairs were placed
in culture medium and 33.33 μM of the test compound for 72 hours, 2 wells per compound.
Effects were assessed microscopically with the same viability scale used for NTS and again,
compounds that achieved an average score of 0.5 or less but after 24 hours were considered as
hits. For further hit characterization, the IC50 values were determined in an adult worm dose-
response assay (33.33, 11.11, 3.70, 1.43 and 0.41 μM drug concentration) at 1, 2, 4, 7, 10, 24,
48 and 72 hours post-drug incubation.
In Vivo Studies in the S.mansoniMouse Model
For in vivo studies, female 3-week old NMRI mice were used. Mice were purchased from
Charles River (Sulzfeld, Germany) and allowed to adapt under controlled conditions (tempera-
ture ca. 22°C; humidity ca. 50%; 12-hour light and dark cycle; free access to rodent diet and
water) for one week. Thereafter, they were infected subcutaneously with approximately 100 S.
mansoni cercariae (obtained as described above). Seven weeks post-infection, 4 mice were
assigned to each drug treatment, while 8 mice were left untreated to serve as controls. Com-
pounds were prepared in a 70:30 Tween/EtOH mixture dissolved in dH2O (10%). Available
compound toxicity data was used to guide the dosing regimen. Compound doses were adjusted
to the mouse weight and were administered orally. Three weeks post-treatment, mice were
killed by the CO2 method and dissected, and the worms were sexed and counted. Mean worm
burdens of treated mice were compared to the mean worm burden of untreated animals and
worm burden reductions were calculated.
Ethics Statement
In vivo studies were conducted at the Swiss TPH, Basel, and approved by the veterinary author-
ities of the Canton Basel-Stadt (permit no. 2070) based on Swiss cantonal (Verordnung Veteri-
näramt Basel-Stadt) and national regulations (the Swiss animal protection law
(Tierschutzgesetz).
Statistics
For in vitro assays, the viability scores were averaged across replicates and normalized to con-
trol-well viability scores using Microsoft Office Excel (2010). IC50 values were computed using
CompuSyn2 (ComboSyn Inc., 2007) by converting viability scores into effect scores for each
drug concentration.
The worm burden (WB) of treated mice was calculated and compared with the worm bur-
den of control mice in order to obtain the worm burden reduction (WBR), calculated as
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follows:
WBR ð%Þ ¼ 100%  ð100% =WBcontrol  WBtreatmentÞ
Statistical comparison was done using the Kruskal Wallis Test and the MannWhitney U
test at a significance level of p< 0.05.
Results
In Vitro Activity on NTS and Adult S.mansoni
The overall screening cascade is presented in Fig 1.
Of the 1600 compounds screened on NTS, 121 compounds (summarized by indication in
Table 1) showed activity at a concentration of 10 μM after 72 hours. Of these, 57 compounds
killed the NTS completely within 72 hours of exposure and 64 compounds damaged the NTS
severely (viability score 0.5, corresponding to a viability of 25%) within the same time
frame. After a quick scan of the hits, 20 compounds were excluded due to their known high
toxicity (e.g. colchicine) or because their activity against S.mansoni has already been described
(e.g. mefloquine) (Table 1).
From the NTS screen, therefore 101 compounds qualified for testing on S.mansoni adult
worms, at a single high concentration of 33.33 μM. Of these, 36 compounds were found to be
active 24 hours post-incubation: the compounds induced death of the worms or a 75% reduc-
tion in their viability (a final viability score of 0.5). However, of the 36 active compounds,
25 were excluded following a closer review for the following reasons: 8 were excluded due to
known toxicity in humans, 9 were indicated for topical use only, 5 had been described to have
toxicity in rodents (low LD50 values), 2 were excluded due to past or current studies conducted
on S.mansoni in vivomodels (niclosamide studied by Abdulla et al. (15); tamoxifen studied by
Cowan et al, submitted for publication), and 1 was rejected due to its poor absorption
(Table 2).
The remaining 11 compounds were further characterized with an IC50 determination assay
at various time-points (Fig 2 and S1 Table). Already after 2 hours incubation, most compounds
(except pimozide, doramectin, clofazimine and flunarazine hydrochloride) exhibited IC50
Fig 1. In vitro screening cascade of the FDA Pharmakon library against S.mansoniNTS and adult worms.
doi:10.1371/journal.pntd.0003962.g001
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values below 10 μM, and by the 10 hour time-point, IC50 values for these compounds ranged
from 1.73–7.80 μM. The fastest acting compounds were nicardipine hydrochloride and oxetha-
zaine, exhibiting IC50 values of 2.67 and 2.95 μM respectively already at 1 hour post-incuba-
tion. Meanwhile, doramectin and clofazimine were the slowest acting, with IC50 values of 16.92
and 20.72 μM respectively at 4 hours post-exposure. Between 24 and 72 hours post-exposure,
IC50 values did not vary greatly between drugs, ranging between 1.34 to 4.17 μM, except for
pimozide which jumped to 8.78 μM at 24 hours and declined to 3.46 μM by the 72-hour time-
point.
These timed IC50 values were compared to available pharmacokinetic data, and all 11 com-
pounds were selected as good in vivo candidates. As previously mentioned, the in vitro data
and available pharmacokinetic and rodent toxicity data were also used to guide the maximum
possible single oral dose regimens.
Table 1. 121 Hit compounds at NTS screening stage.
Antibacterial Cefdinir*; Chloroxine; Clofoctol*; Gentian violet;
Hexachlorophene; Lasalocid sodium; Monensin
sodium*; Narasin; Natamycin; Pyrithione zinc;
Salinomycin sodium*; Sulfanitran; Thonzonium
bromide;
Antipsychotic Aripiprazole; Chlorprothixene hydrochloride*;
Fluphenazine hydrochloride; Metitepine mesylate;
Perphenazine; Pimozide; Prochlorperazine
edisylate; Sertraline hydrochloride (anti-
depressant); Thioridazine hydrochloride;
Trifluoperazine hydrochloride; Triflupromazine
hydrochloride*;
Antifungal Broxaldine; Butoconazole; Candicidin; Ciclopirox
olamine; Econazole nitrate; Hexetidine;
Itraconazole hydrochloride; Miconazole nitrate;
Oxyquinoline sulfate; Phenylmercuric acetate;
Piroctone olamine; Sulbentine; Sulconazole
nitrate; Terbinafine hydrochloride; Thiram;
Antihistamine/ anti-
inflammatory
Azelastine hydrochloride; Betamethasone sodium
phosphate (also immunosuppressant);
Cepharanthine; Cinnarazine; Escin; Montelukast
sodium; Promethazine hydrochloride*; Terfenadine;
Antiprotozoal Mefloquine**; Nifursol; Primaquine phosphate;
Pyronaridine tetraphosphate;
Statins/ Anti-diabetic/
coronary disease
Fluvastatin; Lovastatin; Metformin hydrochloride
(Diabetic); Orlistat; Perhexiline maleate
Anthelminthic Abamectin; Antimony potassium tartrate
trihydrate**; Doramectin; Eprinomectin;
Hycanthone**; Moxidectin; Niclosamide;
Oltipraz**; Praziquantel**; Pyrvinium pamoate;
Quinacrine hydrochloride; Selamectin;
Trichlorfon**
Antihypertensive/
vasodilator
Amlodipine besylate; Fendiline hydrochloride;
Flunarizine hydrochloride; Lomerizine
hydrochloride; Manidipine hydrochloride;
Nicardipine hydrochloride; Prazosin hydrochloride*;
Reserpine; Suloctidil; Vinpocetine
Antiinfective/
antiseptic
Acriflavinium hydrochloride; Benzalkonium
chloride; Benzoxiquine; Bronopol; Cetrimonium
bromide; Mepartricin; Methylbenzethonium
chloride; Nifuroxazide; Thimerosal
Cholinergic/ Anasthetic/
Cardiac stimmulant
Atracurium besylate; Inamrinone; Neostigmine
bromide*; Oxethazaine; Physostigmine salicylate*;
Proscillaridin; Pyridostigmine bromide
Anticancer Arsenic trioxide diethanolamine salt; Tamoxifen
citrate; Toremiphene citrate;
Other Acamprosate calcium; Amsacrine; Chlormadinone
acetate; Clofazimine; Clomiphene citrate**;
Colchicine*; Cyclosporine**; Digitoxin*;
Erythrosine sodium; Idebenone; Iodipamide;
Menadione; Methylene blue; Mifepristone;
Octisalate; Podofilox; Protoporphyrin ix; Riboflavin;
Riboflavin 5-phosphate sodium; Securinine;
Tenylidone; Tolonium chloride; Tolperisone
hydrochloride
Compounds were tested at a concentration of 10 μM and hits were defined as compounds for which the NTS scored  0.5 on our viability scale at 72
hours post-exposure.
*Indicates compound excluded due to toxicity concerns.
**Indicates compound that has already been well-characterized on Schistosoma spp. and hence was excluded.
doi:10.1371/journal.pntd.0003962.t001
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In Vivo Studies in the S.mansoniMouse Model
Dosing, worm burden and worm burden reductions of the 11 compounds tested are presented
in Table 3.
Metitepine mesylate proved to be toxic to mice at each dose tested (400, 200, 100 and 50
mg/kg, one mouse tested per dose and observed) and further investigation with this compound
was ceased. Doramectin exerted a moderate worm burden reduction (60.1%) and clofazimine
Table 2. Compounds active on adult S.mansoni at a concentration of 33.33 μM at 24 hours.
Indication Compound Exclusion
Antibacterial Pyrithione zinc Topical
Gentian violet Topical
Hexachlorophene Topical
Thonzonium bromide Topical
Narasin Toxicity in rodent
Antifungal Miconazole nitrate Topical
Hexetidine Topical
Phenylmercuric acetate Toxic
Anthelminthic Doramectin
Abamectin Toxicity in rodent
Eprinomectin Toxicity in rodent
Pyrvinium pamoate Poor absorption
Niclosamide Being studied
Selamectin Topical
Anti-infective/antiseptic Methylbenzethonium chloride** Topical
Cetrimonium bromide Topical
Thimerosal Toxic
Anticancer Arsenic trioxide diethanolamine salt Toxic
Tamoxifen citrate Being studied
Antipsychotic Pimozide
Metitepine mesylate
Antihistamine/ anti-inflammatory Manidipine hydrochloride
Terfenadine Toxic
Statins/ Anti-diabetic/ coronary disease Perhexiline maleate Toxic
Antihypertensive/ vasodilator Fendiline hydrochloride
Flunarizine hydrochloride
Lomerizine hydrochloride
Nicardipine hydrochloride
Suloctidil Hepatotoxic
Amlodipine besylate Toxicity in rodent
Cholinergic/ Anesthetic/ Cardiac stimulant Proscillaridin Toxicity in rodent
Oxethazaine
Other Menadione
Clofazamine
Tenylidone Topical
Securinine Toxic
Activity was defined as scoring an average of  0.5 on the viability scale. The reason for exclusion is also listed and the data is based on compound
material safety data sheets, FDA documents and previous publications.
doi:10.1371/journal.pntd.0003962.t002
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Fig 2. IC50 values of compounds selected for in vivo testing.
doi:10.1371/journal.pntd.0003962.g002
Table 3. Worm burden reductions of S.mansoni-infectedmice treated with in vitro-hit FDA Pharmakon compounds.
Worm Burden Worm Burden
Reduction (%)
Compound Dose (mg/kg) No. of mice Female Total Female Total
Control Batch 1 Untreated 8 24.1 50.1 - -
Control Batch 2** Untreated 8 14.8 31.3 - -
Clofazimine 400 3* 3.7 8.7 80.8 82.7
Clofazimine** 200 4 19.8 38.5 0 0
Doramectin 10 4 10.3 20.0 62.5 60.1
Fendeline hydrochloride 100 3* 34.0 68.7 0 0
Flunarizine hydrochloride 200 4 18.0 36.8 27.9 26.7
Lomerizine hydrochloride 200 4 24.8 52.5 0 0
Manidipine hydrochloride 100 4 19.3 36.3 34.6 27.7
Menadione 400 4 27.3 53.3 0.0 0
Metitepine mesylate All doses toxic- study stopped N/A N/A N/A N/A N/A
Nicardipine hydrochloride 200 3* 12.3 25.3 50.0 49.5
Oxethazaine 200 3* 16.3 32.3 38.5 35.5
Pimozide 100 4 13.0 25.3 52.6 49.5
*Indicates that the 4th mouse of this group died prematurely.
** WBR for clofazimine (200 mg/kg) was calculated based on worm burden of Control Batch 2.
doi:10.1371/journal.pntd.0003962.t003
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caused a high, however not statistically significant worm burden reduction (82.7%). In a fol-
low-up in vivo study, a dose 200 mg/kg clofazimine was tested in 4 S.mansoni-infected NMRI
mice. Lowering the dose, however, resulted in a complete lack of efficacy (0% female and total
WBR). Pimozide and nicardipine hydrochloride also demonstrated some efficacy (49.5%WBR
for both), whereas mild WBRs were observed for flunarizine hydrochloride (26.7%WBR),
oxethazaine (35.5%WBR) and manidipine hydrochloride (27.7%WBR). Lomerizine hydro-
chloride, fendeline hydrochloride and menadione lacked in vivo activity.
Discussion
The advent of praziquantel in the 1970s was a great milestone for the control of schistosomiasis
in that finally, a safe, cheap and effective drug became available that could be used to treat mil-
lions in cost-effective preventive chemotherapy campaigns. Unfortunately, the success of prazi-
quantel also resulted in many labs and firms choosing to drop further investigations on their
leads [19]. This, along with inadequate attention and funding has rendered the antischistoso-
mal arsenal dangerously dependent on a single drug [10].
As de novo drug discovery becomes increasingly expensive, drug repurposing, on the other
hand, has shown to bear fruit in the antischistosomal drug discovery field as well as others with
fewer resources involved [12,20,21]. By screening a library of well-characterized compounds, it
was our hope to identify new drugs or drug classes that could be explored further in pre-clinical
development. An initial screen against NTS revealed a hit rate of ~7.6% and encompassed a
wide range of compound indications including antipsychotics, antibiotics, antifungals, antihis-
tamines, antihypertensives and even vitamin precursors and metabolites (Table 1). Results of
this work in part mirrored the screen conducted by Abdulla and colleagues (mentioned earlier),
in that the variety of active compounds also ranged across a large spectrum of indications [15].
However, in comparing our NTS hits, it was interesting to note that although there was some
overlap, there were numerous incongruences as well (S2 Table and Fig 3A). Of the 121 NTS
hits we identified in our library, 69 of the compounds were also found in their library, but of
these 69, only 25 were identified as hits (36% overlap). Conversely, of the 105 hits identified in
the library of Abdulla and colleagues, 55 were found in our library and of those, 25 were char-
acterized as hits (45%). These inconsistencies are likely a combination of differences in drug
concentrations used, time of evaluation post-drug exposure and screen cut-off filters for hit
identification, which indicates that these factors can greatly influence the outcome of a screen.
Indeed, a closer inspection of hits identified by Abdulla et al. and missed in our library revealed
that most of these “missed compounds” had some effect on our NTS but not enough to reach
the cut-off threshold. Nonetheless, it may also be possible that strain differences result in differ-
ing drug susceptibilities (Abdulla et al. used a Puerto Rican strain, whereas ours was a Liberian
strain). Indeed, Ingram-Sieber et al. observed similar differential sensitivities from their screen
of MMVMalaria Box compounds conducted by two independent labs using exactly these two
strains [16]. Bearing these incongruences in mind, it might be useful to start a discussion on a
possible need for standardization and replication.
Recently, Neves et al, took advantage of the published genome and transcriptome of S.man-
soni [22] as well as public drug databases to conduct an in silico screen of compounds with
known targets that theoretically match targets found in the S.mansoni genome and transcrip-
tome [17]. When we compared their hits to our NTS hits, a moderate overlap was observed (S2
Table and Fig 3B). In more detail, of the 162 compounds described to match to an S.mansoni
target in silico (115 compounds they describe as novel along 47 with compounds for which
some activity has already been described), 102 were present in our library, and of these 102, 19
were deemed as active, corresponding to a 19% overlap. The fact that the in silico prediction
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did not strongly match our in vitro hits, doesn’t necessarily mean the in silico hits are incorrect:
they could be differentially active on other life stages (ex. juvenile), active in vivo, at a higher
concentration, or, as we saw with Abdulla and colleagues, in a different screen with a different
strain. Nonetheless, it does hint that target-based approaches still require further development.
In this screen we identified doramectin and clofazimine as two moderately active com-
pounds against S.mansoni in an NMRI mouse infection model (Fig 4).
The activity of doramectin, though not statistically significant, is nonetheless surprising:
studies in S.mansoni-infected mice with the highly related ivermectin showed minimal efficacy
when administered as a single oral dose of 25 mg/kg [23]. Moreover, clinical trials with iver-
mectin showed little efficacy against intestinal and urinary schistosomiasis [24]. However, dor-
amectin is reported to have more favorable pharmacokinetic properties, which could account
for its higher in vivo efficacy in our study [25]. Doramectin has not been previously studied in
humans and therefore would need substantial efforts to register the drug for human medicine.
However, the closely related moxidectin has shown a moderate effect against S.mansoni in pre-
liminary clinical studies [26]. Moxidectin was active against NTS and moderately active against
the adult stage worm in our screen, and hence may be worthy of further investigation.
Fig 3. Venn diagrams representing overlaps between: (A) our NTS screen and that of Abdulla et al., (B) our NTS screen and in silico hits from
Neves et al. and (C) NTS hits from Abdulla et al. and hits from Neves et al. The small dark circles within each large circle represent the number of
compounds that were not present in the comparator’s library.
doi:10.1371/journal.pntd.0003962.g003
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Clofazimine is originally indicated for treatment against leprosy and is on the WHOModel
List of Essential Medicines [27]. It is a fat-soluble iminophenazine dye that has demonstrated
immunosuppressive properties, including inhibition of macrophages, neutrophil motility, lym-
phocyte transformation and mitogen-induced PBMC formation [28–30]. Recently, clofazimine
was also identified as a promising preclinical anti-trypanosomal agent in an in silico screen of
marketed drugs [31]. The authors noted that the compound was also effective in inhibiting epi-
mastigote proliferation in vitro and in reducing parasitaemia levels in a murine infection
model at a dose of 20 mg/kg. In our study, the initial dose of 400 mg/kg clofazimine showed a
moderately high WBR (82.7%), while lowering the dose to 200 mg/kg was not effective. Con-
sidering the long half-life of clofazimine (12–15 hours) as well as its reportedly good absorption
(60–100%), we deemed it unnecessary to study the effects of multiple dosing. Currently, off-
label use of clofazimine is highly discouraged by the WHO, as it is the first line of treatment
against leprosy and there are legitimate fears of drug resistance [32]. Nonetheless, it may be
worth exploring the antischistosomal activities of related structures.
With the advent of the S.mansoni genome, there have been attempts to incorporate rational
drug screening in the antischistosomal drug discovery process. Recently, the observation that
fatty acids play a major role in schistosome development, fecundity and tegument construction
has spurred researches to investigate the potentials of cholesterol-lowering statins [33–36].
Consequently, Rojo-Arreola and colleagues evaluated six statin compounds, atorvastatin,
Fig 4. Structures and pharmacokinetic data of in vivo-active clofazimine (A) and doramectin (B). Clofazimine data is based on a single oral dose of 200
mg give to healthy male volunteers [45]. Doramectin data is based on a single oral dose of 200 μg/kg administered to horses [46].
doi:10.1371/journal.pntd.0003962.g004
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fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin, all targeting 3-hydroxy-
3-methylglutaryl coenzyme A reductase (HMGR) of the eukaryotic mevalonate pathway on S.
mansoni NTS and adult worms. All drugs were found to be active in vitro and targeted
SmHMGR [37]. In our own screen, fluvastatin and lovastatin were found to be active on NTS
but inactive on adult worms. Atorvastatin and simvastatin were inactive already at the NTS
stage and pravastatin and rosuvastatin were not present in our library. The contrasting results
could be partly attributed to the stricter cut-off parameters used in our screen (shorter drug
incubation time, only severe reduction in viability considered) or could also be due to strain
differences (the use a Puerto Rican strain). In vivo tests would be required to say anything sub-
stantial about the potential of statins as antischistosomals.
Considering rational S.mansoni drug targets, it was interesting to note that none of the cal-
cium channel blockers such as fendeline hydrochloride or flunarizine hydrochloride showed a
potent in vivo effect. In light of the notion that praziquantel’s mode of action is highly sus-
pected to be due its disruption of Ca2+ homeostasis, the idea that known calcium channel
blockers could be effective against S.mansoni in vivo is not too far-fetched [38,39]. That being
said, these drugs are often used to treat chronic human disorders such as hypertension,
migraines or allergies, meaning they also bind to human receptors. The fact that these drugs
were very potent in vitro but not in vivo could be attributable to many factors such as drug
metabolism or protein binding, but competition between host and parasite receptors might
play a role. This could be a general drawback to repurposing drugs with known human recep-
tor targets for use against parasite infections.
Indeed, while drug repurposing can potentially reduce the time and costs of the drug discov-
ery process, its limitations should also be carefully considered and are already observable in
our study. Although compound libraries intended for new indication screens often contain
already marketed drugs, their safety window may not necessarily be acceptable for schistosomi-
asis treatment and preventative chemotherapy. Drug repurposing is a popular strategy for an
array of diseases, some of which a narrow safety window is acceptable due to the nature of the
disease [40,41]. Compounds chosen for development against schistosomiasis, however, must
have an excellent safety profile, as they will be very widely used in preventive chemotherapy
campaigns mainly targeted towards children [42]. Indeed, of the 36 adult worm hits, it was
disappointing to note that 25 of these compounds were unsuitable for testing, notably due to
documented severe side-effects, restriction to topical use or low LD50 values in mice. Some
compounds, for example terfenadine, had even been withdrawn from FDA approval or were
no longer marketed [43]. It would be favorable if further libraries of already known compounds
would be strictly composed of drugs currently on the market with a good safety profile, in
order for a real drug repurposing effort to be possible.
A further major challenge to drug repurposing might be the difficulty to develop a dose regi-
men in humans that provides plasma exposure in the range of the in vitro IC50 concentration,
which tends to be high for helminths. Hence the chance that safety, pharmacokinetics and
pharmacological action will match for a very different indication is uncertain. With these limi-
tations in mind, the NTD community should not rely on drug repurposing alone as a drug dis-
covery strategy. Nonetheless, it is a very worthy venture: as previously stated, many of the
anthelmintics used today were repurposed from veterinary applications [12]. Moreover, 90%
of the drugs available today have secondary indications, showing that repurposing continues to
be a popular strategy both for academia and industry [44]. Importantly, each marketed drug
very likely has a library of analogues behind it, with which structure activity relationship for a
hit expansion program can certainly be envisaged. Access to these analogues would facilitate
an optimization program aiming at the identification of preclinical candidates.
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In conclusion, by screening a library of 1600 well characterized compounds, we have identi-
fied dozens of compounds active against S.mansoni in vitro. Many of the compounds safety or
pharmacokinetic profiles rendered them unfavorable for further exploration. Nonetheless, of
the 11 compounds screened in vivo, we identified two compounds with moderate to high activ-
ities with which further investigations may result in novel compound class treatments.
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